30/07/2016 07:10:21 1-888-992-3836 (toll free) Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
07/29/20161:47PMDJNMerck Revenue Rises on Cancer, Hepatitis Treatments -- Update
By Peter Loftus and Austen Hufford Merck & Co. posted an unexpected increase in second-quarter revenue thanks to new cancer and hepatitis treatments, and an increased profit versus a year-earlier period that was weighed down by foreign-exchange losses. The drugmaker also tightened its full-year 2016 financial forecast... More...>>
07/28/20161:26PMDJNBristol-Myers Results Boosted by Cancer Drugs -- Update
By Jonathan D. Rockoff and Tess Stynes Bristol-Myers Squibb Co. said its second-quarter revenue rose 17% and it raised its earnings forecast for the year as the company's bet on cancer immunotherapies continues to pay off while other drugs show gains. The drugmaker was the first to bring to market an immunotherapy... More...>>
07/28/20167:50AMDJNBristol-Myers Results Boosted by Cancer Drugs
Bristol-Myers Squibb Co. said its second-quarter revenue rose 17%, again driven by the growth of the pharmaceutical company's Opdivo cancer immunotherapy and other key drugs. Per-share earnings and revenue beat expectations, and the company also raised its 2016 guidance. For the year, Bristol-Myers now expects per-share... More...>>
07/28/20167:30AMDJNBristol-Myers Results Boosted by Cancer Drugs
By Tess Stynes Bristol-Myers Squibb Co. said its second-quarter revenue rose 17%, again driven by the growth of the pharmaceutical company's Opdivo cancer immunotherapy and other key drugs. Per-share earnings and revenue beat expectations, and the company also raised its 2016 guidance. For the year, Bristol-Myers... More...>>
07/28/20166:59AMBWBristol-Myers Squibb Reports Second Quarter Financial Results
Increases Second Quarter Revenues 17% to $4.9 Billion Posts Second Quarter GAAP and Non-GAAP EPS of $0.69 Achieves Important Regulatory Milestones in Immuno-Oncology Opdivo + Yervoy Regimen Approved in Europe for Metastatic Melanoma Opdivo Approved in the U.S. for the Treatment of Classical Hodgkin Lymphoma Opdivo Granted... More...>>
07/27/20166:10PMDJNExperimental Alzheimer's Drug Fails in Trial
An experimental drug for Alzheimer's targeting a protein called tau failed to improve patients' cognition or daily functioning in a clinical trial, dealing a setback to a closely watched segment of research. The treatment, from Singapore-based drugmaker TauRx Pharmaceuticals Ltd., was the first tau-targeted therapy... More...>>
07/26/20166:59AMBWBristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung Cancer
Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin... More...>>
07/25/201611:00AMBWBristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Fouad Namouni, M.D., has been appointed Oncology Development Head, effective July 25, 2016. Dr. Namouni will be responsible for leading the execution of a comprehensive development strategy for the company’s robust oncology pipeline from the early development... More...>>
07/25/20166:59AMPRNUSAbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo an...
AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen - Collaboration will explore the safety and potential enhanced efficacy of combining checkpoint inhibitors with a cancer stem cell-targeting antibody drug conjugate in SCLC... More...>>
07/25/20166:59AMBWCHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of Highly Active & Progressive Disease in Adult Patie...
If approved for the new indication, ORENCIA would be the first biologic therapy with an EU indication specifically applicable to the treatment of MTX-naive RA patients with highly active and progressive disease Would mark the first time that MRI assessment of structural and inflammatory measures of disease severity are... More...>>
07/25/20166:59AMBWAbbVie & Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo & Op...
Collaboration will explore the safety and potential enhanced efficacy of combining checkpoint inhibitors with a cancer stem cell-targeting antibody drug conjugate in SCLC Expect to begin patient enrollment in 2016 AbbVie (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) today announced a clinical trial collaboration... More...>>
07/20/201611:39AMBWBristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcutane...
ORENCIA is the only biologic treatment for moderate to severe rheumatoid arthritis that is approved in three administration options – IV infusion, prefilled syringe, and autoinjector1-10 New ORENCIA ClickJect Autoinjector offers accurate dose self-injection with push button operation, and confirmation that the full dose... More...>>
07/20/20166:59AMBWBristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcutane...
ORENCIA is the only biologic treatment for moderate to severe rheumatoid arthritis that is approved in three administration options – IV infusion, prefilled syringe, and autoinjector1-10 New ORENCIA ClickJect Autoinjector offers accurate dose self-injection with push button operation, and confirmation that the full dose... More...>>
07/18/20166:59AMBWBristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamo...
U.S. Food and Drug Administration and European Medicines Agency accept marketing applications for Opdivo in this patient population Regulatory submissions based on CheckMate -141, in which Opdivo met its primary endpoint of overall survival, compared to investigator’s choice of therapy Bristol-Myers Squibb Company (NYSE:BMY... More...>>
07/11/20167:55AMPRNUSTechnical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline PR Newswire NEW YORK, July 11, 2016 NEW YORK, July 11, 2016 /PRNewswire/ -- On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average... More...>>
07/05/20169:20AMDJNBristol-Myers Buys Swedish Firm With Immunotherapy Treatment
Bristol-Myers Squibb Co. said Tuesday that it had acquired Sweden-based Cormorant Pharmaceuticals for up to $520 million, the drugmaker's latest deal involving products that harness the immune system to attack cancerous tumors. Under the deal, Bristol-Myers will pay $95 million in upfront and near-term payments to... More...>>
07/05/20169:12AMDJNBristol-Myers Buys Swedish Firm With Immunotherapy Treatment
By Brittney Laryea Bristol-Myers Squibb Co. said Tuesday that it had acquired Sweden-based Cormorant Pharmaceuticals for up to $520 million, the drugmaker's latest deal involving products that harness the immune system to attack cancerous tumors. Under the deal, Bristol-Myers will pay $95 million in upfront and near-term... More...>>
07/05/20166:59AMBWBristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Gains full-rights to Cormorant’s HuMax-IL8 antibody program and lead asset HuMax-IL8 in Phase 1/2 Development Broadens Bristol-Myers Squibb’s oncology pipeline focus on the tumor microenvironment and combination therapy Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers... More...>>
06/30/20166:59AMBWBristol-Myers Squibb & PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Op...
Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers... More...>>
06/30/20166:59AMBWBristol-Myers Squibb & PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Op...
Bristol-Myers Squibb Company (NYSE:BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20160730 11:10:23